Trial Profile

A phase 1 trial first-in-human, open-label, multicenter, single injection, dose-escalation study of EB-105 in patients with Diabetic Macular Edema (DME)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2025 According to an Eluminex Biosciences media release, Part 2 of this study will be conducted with multiple ascending doses in a similar DME population evaluating the same three dose levels as assessed in Part 1 and will be conducted at up to 10 sites in the United States,Expected to begin enrollment in Q3 2025.
09 Jun 2025 According to an Eluminex Biosciences media release, the study results (Part 1) ,will be presented at the Clinical Trials at the Summit annual meeting in Las Vegas, NV on June 21, 2025.
09 Jun 2025 Results (Part 1) from this study presented in the Eluminex Biosciences Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com